EUVIMEDEUVIMED entdecken
Crossref

Sophocarpine alleviates cancer-induced bone pain by inhibiting Nav1.7 and NGF-TrkA-SGK1 pathway

Li Gao iD, Xin-Yue Zhang, Xin-Le Zhou, Zhan-Shuo Cui, Wen-Qian Du, Rong-Li You, An-Ping Li, Jing Zhao iD

Journal of Pharmacy and Pharmacology · 04.11.2026 · 78 (11)

DOI: 10.1093/jpp/rgag132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 09.11.2026. Verfasst von Li Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, China. Hauptthemen laut MEDLINE: NAV1.7 Voltage-Gated Sodium Channel, Alkaloids, Cancer Pain, Protein Serine-Threonine Kinases. Die Arbeit nennt 51 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Traditional Chinese Medicine Innovation Team of Shanxi Province, Key Laboratory of Comprehensive Utilization Research on Shanxi Genuine Medicinal Materials.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Voltage-gated sodium channel subtype 1.7 (Nav1.7) is a promising target for cancer-induced bone pain (CIBP), but existing inhibitors show limited clinical efficacy. We previously demonstrated that Compound Kushen Injection (CKI) alleviates CIBP in female rats by inhibiting Nav1.7 expression, but its bioactive constituents remained unclear. This study aimed to identify the active constituent in CKI responsible for Nav1.7 inhibition and to elucidate its mechanism of analgesic action in CIBP.

Methods

CKI constituents were systematically screened for inhibitory activity against Nav1.7 expression, and the analgesic efficacy of sophocarpine (SC) was evaluated in a female rat model of CIBP. Western blot, immunofluorescence, and quantitative real-time PCR were used to investigate the mechanisms of SC in the alleviation of CIBP. Key findings SC was identified as a potent Nav1.7 expression inhibitor, with an IC50 of 0.002 μg/ml, much lower than that of PF-05089771 (IC50 = 0.120 μg/ml). In vivo, SC alleviated nociceptive hypersensitivity and spontaneous pain in female CIBP rats. Furthermore, SC suppressed Nav1.7 expression in spinal cord and dorsal root ganglia, and also downregulated nerve growth factor, tropomyosin receptor kinase A, and serum and glucocorticoid-regulated kinase 1, while inhibiting phosphorylation of neural precursor cell expressed developmentally down-regulated 4-2 and extracellular signal-regulated kinase 1/2.

Conclusions

This study identifies SC as an inhibitor of Nav1.7 expression, providing a promising lead compound for CIBP treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NAV1.7 Voltage-Gated Sodium ChannelAlkaloidsCancer PainProtein Serine-Threonine KinasesAnalgesicsBone NeoplasmsAnimalsFemaleRatsNerve Growth FactorRats, Sprague-DawleyReceptor, trkAMatrinesSignal TransductionDisease Models, Animal

Stichwörter der Autor:innen

NEDD4-2NGF-TrkA-SGK1Nav1.7cancer-induced bone painp-ERK1/2sophocarpine

Substanzen

NAV1.7 Voltage-Gated Sodium ChannelAlkaloidssophocarpineProtein Serine-Threonine KinasesScn9a protein, ratNerve Growth FactorReceptor, trkAAnalgesicsMatrinesNgf protein, rat

Autor:innen und Institutionen

  • Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, China.
  • Shanxi Key Laboratory of Research and Utilization of Bioactive Components in Famous Medicinal Materials, Taiyuan 030006, China.
  • Shanxi Center For Drug Evaluation (Shanxi Institute of Medicine and Life Sciences), Taiyuan 030006, China.
  • Shanxi Zhendong Pharmaceutical Co., Ltd., Changzhi 047100, China.
  • Shanxi ZhenDong Health Industry Group Co., Ltd., Changzhi 046000, China.
  • Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, United Kingdom.

ORCID-Profile: Li Gao, Jing Zhao

Förderung

  • China Postdoctoral Science Foundation
  • Traditional Chinese Medicine Innovation Team of Shanxi Province
  • Key Laboratory of Comprehensive Utilization Research on Shanxi Genuine Medicinal Materials

Zitieren

APA

Gao, L., Zhang, X. Y., Zhou, X. L., Cui, Z. S., Du, W. Q., You, R. L., Li, A. P., & Zhao, J. (2026). Sophocarpine alleviates cancer-induced bone pain by inhibiting Nav1.7 and NGF-TrkA-SGK1 pathway. Journal of Pharmacy and Pharmacology, 78(11). https://doi.org/10.1093/jpp/rgag132

Vancouver

Gao L, Zhang XY, Zhou XL, Cui ZS, Du WQ, You RL, et al. Sophocarpine alleviates cancer-induced bone pain by inhibiting Nav1.7 and NGF-TrkA-SGK1 pathway. Journal of Pharmacy and Pharmacology. 2026;78(11). doi:10.1093/jpp/rgag132

BibTeX
@article{Gao2026,
  author = {Gao, Li and Zhang, Xin-Yue and Zhou, Xin-Le and Cui, Zhan-Shuo and Du, Wen-Qian and You, Rong-Li and Li, An-Ping and Zhao, Jing},
  title = {Sophocarpine alleviates cancer-induced bone pain by inhibiting Nav1.7 and NGF-TrkA-SGK1 pathway},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  volume = {78},
  number = {11},
  doi = {10.1093/jpp/rgag132}
}
Kostenlos starten →